Playbook for Platform Selection, Bolt-On Sequencing and Multiple Arbitrage: Buy and Build in European HealthTech

Buying at 6x EBITDA and selling at 10x to 14x EBITDA only works if the platform actually integrates; in HealthTech, most don't. In the European lower mid-market, private equity sponsors frequently default to traditional roll-up playbooks perfected in physical healthcare services, such as dental networks, veterinary chains, or primary care clinics. In physical services consolidation, value creation relies on centralising back-office functions, such as procurement, payroll, billing and scheduling, while leaving local clinical operations largely autonomous. Applying this surface level roll-up strategy to clinical software and HealthTech assets repeatedly triggers severe operational stagnation and value destruction.
  
Unlike physical clinic branches, clinical software assets cannot exist as autonomous, siloed outposts under a shared corporate umbrella. Digital health assets operate within highly complex, tightly coupled clinical workflows, heterogeneous data environments, and stringently enforced regulatory frameworks. When acquired software assets fail to integrate at the codebase, data schema, and quality management levels, expected cost and revenue synergies evaporate. Instead, platforms become clogged with compounding technical debt, escalating customer acquisition costs (CAC), provider pushback and elevated customer churn.
  
Despite these operational risks, private equity commitment to European healthcare technology remains intense. Sponsor buyout volume in European healthcare surged by 276% year-over-year to €29.6 Billion, pushing total transaction value to €31.8 Billion across the first half of 2025 alone. Driven by massive dry powder reserves and a fundamentally fragmented European market, lower mid-market investors view buy-and-build as their primary strategy for scaling assets with $5 Million to $10 Million in EBITDA. Achieving true multiple arbitrage, however, requires moving beyond financial engineering to master the operational mechanics of clinical software integration, regulatory sequencing and architectural unification.

Strategic Guidance for Private Equity Investment Committees and Operating Partners
  
To successfully execute lower mid-market buy-and-build strategies in European HealthTech, private equity sponsors and operating partners should adopt the following operational guidelines:

Enforce Technical Due Diligence Before Capital Commitment: Prioritize codebase hygiene and cloud-native architecture over pure top-line revenue scale. Reject platform targets that consist of unintegrated collections of legacy codebases. Ensure the platform asset features open RESTful APIs, modern micro-services and native FHIR/OMOP compatibility prior to executing the initial transaction.

Sequence Bolt-Ons by Regulatory Complexity: Structure acquisition schedules to manage operational risk. Acquire low-risk administrative, practice management, and billing software in Year 1 to expand market footprint and compress acquisition costs. Defer high-burden, MDR/IVDR-regulated diagnostic and AI targets to Years 2 and 3, after centralising Quality Management System infrastructure.

Unify Go-to-Market Infrastructure Within 90 Days: Eliminate redundant ad spend and agency sprawl immediately following acquisition. Centralising digital marketing and patient acquisition infrastructure prevents CAC multiplication, protecting portfolio EBITDA from margin compression.

Convert Regulatory Frameworks into Competitive Moats: Invest early in establishing a centralized Quality Management System compliant with ISO 13485, EU MDR, IVDR, and the EU AI Act. Transforming regulatory compliance into shared platform infrastructure allows the platform to absorb smaller targets efficiently, establishing market entry barriers that command premium multiples at exit.

Click here to read the full report https://www.healthcare.digital/single-post/buy-and-build-in-european-healthtech-a-playbook-for-platform-selection-bolt-on-sequencing-and-mult